Clinical Application of TKD-36 (Moku-boi-to) on Chronic Heart Failure in Dogs.
スポンサーリンク
概要
- 論文の詳細を見る
A multi-central clinical trial was conducted to assess the effect of TKD-36 (Moku-boi-to)on chronic heart failure in dogs. TKD-36 (75, 150 or 300 mg/kg/day, divided b. i. d., p. o.) or placebo were administered for 4 weeks to dogs showing signs of chronic heart failure. Overall assessment and various clinical evaluation of clinical symptoms in dogs treated with TKD-36 (150 and 300 mg/kg/day) were excellent compared to that in dogs treated with the placebo. But the dose of 75 mg/kg/day of TKD-36 did not improve any clinical signs of heart failure as same as the placebo group. No adverse reactions attributable to TKD-36 administration were observed, confirming its safety in this species. Based on efficacy, safety and overall assessment analyses, the optimal dosage of TKD-36 is from 150 to 300 mg/kg/day.<BR>These results clearly indicate that TKD-36 is an excellent drug for a treatment of the chronic heart failure in dogs.
- 日本獣医循環器学会の論文
日本獣医循環器学会 | 論文
- ヒトの特発性心筋症の遺伝子解析
- 遺伝子診断法
- 部分内臓逆位, 肝部後大静脈欠損および奇静脈連結を伴う静脈管開存症の犬の1例
- 右前大静脈欠損を伴う左前大静脈遺残の犬の一例
- 長期観察が可能であった猫拡張型心筋症の1例